Pre-earnings brief
Reports
Wed, Nov 11, 2026
Est. EPS
—
Est. revenue
—
Implied move
±18.0%
EPS beat rate
75%
Celcuity Inc. is a biotechnology company focused on developing innovative treatments for cancer. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as the demand for effective cancer therapies continues to grow.
Last quarter
In Q2 2026, Celcuity reported an EPS of -$1.07, slightly beating expectations of -$1.08. The stock reacted negatively, dropping 5.95% the following day.
EPS beat streak
6Q
EPS beat rate
75%
Avg EPS surprise
+9.32%
Avg 1-day reaction
+1.56%
Investors are cautiously optimistic about Celcuity's upcoming earnings, especially given its recent history of beating EPS estimates. However, there is uncertainty about revenue figures as no estimates are available.
Bull case
If Celcuity continues its trend of beating EPS estimates, it could signal strong operational performance and potentially lead to a positive stock reaction.
Bear case
On the other hand, if the company fails to meet expectations or provides no guidance, it could raise concerns about its future growth prospects and negatively impact the stock.
The print will turn on these.
Q1
What will the EPS be for Q3-2026?
Given Celcuity's recent history of beating EPS estimates, this number will be crucial for investor sentiment and stock performance.
Q2
What guidance, if any, will management provide for future revenue?
Investors are looking for clarity on revenue growth to assess the company's future prospects and market position.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±10.3%
Why consensus could be wrong
The Street may be underestimating Celcuity's potential for a significant EPS beat, given its recent track record of surprises.
Supporting evidence
Celcuity has beaten EPS estimates in 75% of the last 8 quarters, indicating a strong operational performance.
The options market is pricing in a larger move than historical averages, suggesting heightened expectations.
Recent trends show that the company has consistently surprised positively, which may not be fully reflected in current sentiment.
Key risk
If the EPS comes in above -$1.00, it could significantly shift market sentiment.
Pre-commit to what would confirm each case.
The market is debating Celcuity's ability to maintain its recent performance and provide clarity on future growth.
Bull confirmed if
A positive EPS surprise of at least 10% would confirm the bull case.
Bear confirmed if
An EPS miss or lack of guidance could confirm the bear case.
What the market is pricing for the move.
Implied Move
±18.0%
Historical Avg
±4.5%
The options market is pricing in a significant move for Celcuity's stock, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±18.0% while CELC has averaged ±4.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
51.7%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 10 of 30 (33%)
This setup has occurred 30 times across Health Care in the last 2 years. 20 of 30 (67%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 3.6%, with a raw directional average of +0.1% (roughly flat historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Celcuity beats expectations, history suggests the stock could rise by around 2.89% on the following day, confirming positive momentum.
In line / cautious
If results are in line but management is cautious, the stock may react mutedly, reflecting uncertainty about future growth.
Miss
If the company misses expectations, history suggests a potential decline of about 2.44%, indicating investor disappointment.
The lines on the call that would change the story.